Filtered By:
Condition: Atrial Fibrillation
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 563 results found since Jan 2013.

Atrial fibrillation in patients with haemophilia: a cross‐sectional evaluation in Europe
Summary Atrial fibrillation (AF) is a common health problem in the general population, but data on prevalence or management in patients with haemophilia (PWH) are lacking. The aims of this study were to analyse the prevalence of AF and risk factors for stroke using a cross‐sectional pan‐European design and to document current anticoagulation practice. The ADVANCE Working Group consists of members from 14 European haemophilia centres. Each centre retrieved data on their PWH with AF. From the total of 3952 adult PWH, 33 had AF with a mean age of 69 years (IQR 62–76). Haemophilia was severe in seven (21%), moderate in ...
Source: Haemophilia - March 1, 2014 Category: Hematology Authors: Roger E. G. Schutgens, R. Klamroth, I. Pabinger, M. Malerba, G. Dolan, Tags: Original Article Source Type: research

CardioPulse Articles * Warfarin increases stroke risk in atrial fibrillation * Aspirin still overprescribed for stroke prevention in atrial fibrillation * Clinical Research in Cardiology: the official journal of the German Cardiac Society (Deutsche Gesellschaft fur Herz-/Kreislaufforschung) * Septic shock in infective endocarditis * Innovation in atrial fibrillation therapy
Source: European Heart Journal - June 7, 2014 Category: Cardiology Tags: CardioPulse Source Type: research

Abstract 15: Frequency and Predictors of Inappropriate Aspirin Prescribing for Primary Prevention of Cardiovascular Disease: Insights from the NCDR(R) PINNACLE Registry. Session Title: Concurrent I Session C: Young Investigator Award Finalists Oral Abstract Presentations
Conclusion: Inappropriate aspirin prescribing occurs in approximately one third of patients receiving aspirin for primary prevention. There is modest but significant practice-level variation. Our findings identify opportunities to improve evidence-based aspirin prescribing in primary CVD prevention.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Hira, R. S., Kennedy, K. F., Nambi, V., Jneid, H., Alam, M., Basra, S. S., Ho, M., Deswal, A., Ballantyne, C. M., Petersen, L. A., Virani, S. S. Tags: Session Title: Concurrent I Session C: Young Investigator Award Finalists Oral Abstract Presentations Source Type: research

Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial
Conclusion The efficacy and safety of apixaban compared with aspirin is consistent in subgroups of patients who have previously attempted but failed VKA therapy, irrespective of the reason for discontinuation.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Coppens, M., Synhorst, D., Eikelboom, J. W., Yusuf, S., Shestakovska, O., Connolly, S. J. Tags: Atrial fibrillation Source Type: research

Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention A Contemporary Review
Chronic oral anticoagulant therapy is recommended (class I) in patients with mechanical heart valves and in patients with atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category) score ≥1. When these patients undergo percutaneous coronary intervention with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes indicated. Before 2014, guidelines recommended the use of triple therapy (vitamin K antagonists, aspirin, and clopidog...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - September 15, 2014 Category: Cardiology Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Cardiology Clinics - September 4, 2014 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Efficacy and Safety of Novel Oral Anticoagulants in Patients with Cervical Artery Dissections
We report on the use, safety, and efficacy of NOACs in the treatment of CAD. Methods: We retrospectively identified patients diagnosed with CAD at a single academic center between January 2010 and August 2013. Patients were categorized by their antithrombotic treatment at hospital discharge with a NOAC (dabigatran, rivaroxaban, or apixaban), traditional anticoagulant (AC: warfarin or treatment dose low-molecular weight heparin), or antiplatelet agent (AP: aspirin, clopidogrel, or aspirin/extended-release dypyridamole). Using appropriate tests, we compared the baseline medical history, presenting clinical symptoms and initi...
Source: Cerebrovascular Diseases - November 12, 2014 Category: Neurology Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Cardiology Clinics - September 1, 2014 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Implications for your practice: Important changes in the 2014 guideline for the management of patients with atrial fibrillation.
Authors: Littrell R, Flaker G Abstract Atrial fibrillation (AF) is an increasingly common cardiac arrhythmia, currently affecting more than 5 million Americans. Management of patients with AF can be complex, with key strategies including selecting rhythm control versus heart rate control and reducing the patient's risk of stroke or other systemic embolization. The American Heart Association, American College of Cardiology, and Heart Rhythm Society released 2014 Guideline for the Management of Patients with Atrial Fibrillation, which outlines several new recommendations with important clinical implications. Among th...
Source: Postgraduate Medicine - April 1, 2015 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation.
Abstract Atrial fibrillation (AF) is the most commonly observed rhythm disorder in clinical practice. It is associated with a high risk of thromboembolic stroke and increased cardiovascular mortality. Vitamin K antagonists (VKAs), the only oral anticoagulants used for thromboembolic prophylaxis in AF patients over the past 60 years, have been effective in reducing thromboembolic stroke, compared with placebo and aspirin, in this group of patients. However, VKAs have a very narrow therapeutic window, so regular monitoring of the therapeutic effect is obligatory for their use. The need for regular assessment of bloo...
Source: Circulation Journal - April 2, 2015 Category: Cardiology Authors: Santarpia G, Curcio A, Sibilio G, Indolfi C Tags: Circ J Source Type: research

Reply: Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: A prospective observational study
We agree with the content of the letter from Dr Jolobe OMP and, specifically we concur with his conclusion, where he underlines the fragile evidence for aspirin use in the prevention of atrial fibrillation (AF)-related stroke. According to recent European guidelines [1], our study aimed to assess prevalence of and variables associated with under-prescription of currently recommended anticoagulant therapy for AF patients, including vitamin K antagonists (VKAs) and new direct oral anticoagulants (DOAs), but not those associated with use or under-use of aspirin, which is currently not recommended for prevention of AF-related stroke.
Source: International Journal of Cardiology - April 15, 2015 Category: Cardiology Authors: M. Bo, F. Li Puma, M. Badinella Martini, Y. Falcone, M. Iacovino, E. Grisoglio, M. Bonetto, G. Isaia, G. Ciccone, G.C. Isaia, F. Gaita Tags: Letters to the Editor Source Type: research

Prevalence and antithrombotic management of atrial fibrillation in hospitalised patients
Conclusions This hospital-based study revealed high AF prevalence rates (16.8%). Patients with AF were present in all hospital zones and almost all patients were at high risk for stroke. Anticoagulation management was likely inappropriate in 48.7%, indicating the need for better guideline implementation initiatives to guarantee hospital-wide optimised care for patients with AF.
Source: Heart - May 12, 2015 Category: Cardiology Authors: Berti, D., Moors, E., Moons, P., Heidbuchel, H. Tags: Drugs: cardiovascular system, Hypertension Arrhythmias and sudden death Source Type: research

Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular AFOral Anticoagulation, Aspirin, or No Therapy in Nonvalvular AF
Even a single additional stroke risk factor in patients with atrial fibrillation may confer a risk of stroke, but what's the best treatment? Journal of the American College of Cardiology
Source: Medscape Today Headlines - May 20, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Updates in perioperative medicine
CONCLUSIONSThe body of literature reviewed provides important information for clinicians caring for surgical patients across multiple fronts, including preoperative risk assessment, medication management, and postoperative medical care. Journal of Hospital Medicine 2015. © 2015 Society of Hospital Medicine
Source: Journal of Hospital Medicine - September 18, 2015 Category: Hospital Management Authors: Suparna Dutta, Steven L. Cohn, Kurt J. Pfeifer, Barbara A. Slawski, Gerald W. Smetana, Amir K. Jaffer Tags: Reviews Source Type: research

Cochrane corner: vitamin K for improved anticoagulation control in patients receiving warfarin
There has been a substantial increase in the use of oral anticoagulants, notably in the ageing population. This is primarily driven by the use of warfarin in people with atrial fibrillation (AF) in order to reduce the risks of thromboembolic events such as stroke.1 In elderly patients with AF, warfarin use has been shown to reduce the relative risk of stroke by >50% compared with aspirin alone.2 Warfarin is also used to treat patients with deep vein thrombosis, mechanical heart valve replacement, cardioversion, cardiomyopathy and antiphospholipid syndrome.1 The clinical benefits of warfarin must also be balanced with po...
Source: Heart - October 11, 2015 Category: Cardiology Authors: Mahtani, K. R., Nunan, D., Heneghan, C. Tags: Drugs: cardiovascular system, Cochrane Corner, Venous thromboembolism, Epidemiology Editorials Source Type: research